Aktie BIOC GLAXOSMITHKLINE S.A.E
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen GlaxoSmithKline S.A.E

Aktien

BIOC

EGS38171C012

BIOC

Schlusskurs Egyptian Exchange
Andere Börsenplätze
 00:00:00 23.05.2024 		% 5 Tage % 1. Jan.
28,98 EGP +0,24 % Intraday Chart für GlaxoSmithKline S.A.E +2,37 % -18,48 %
04.03. GlaxoSmithKline S.A.E. meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2023 CI
2023 GlaxoSmithKline S.A.E. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2023
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2022
GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2021
GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision
GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
GlaxoSmithKline S.A.E Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021
Glaxosmithkline S.A.E Reports Standalone and Consolidated Financial Results for the Quarter Ended March 31, 2021
Glaxosmithkline S.A.E Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2020
Hikma Pharmaceuticals PLC cancelled the acquisition of GlaxoSmithKline S.A.E.
Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline Shares
Hikma Pharmaceuticals PLC entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E from Glaxo Group Limited.
GlaxoSmithKline S.A.E Reports Audited Standalone Earnings Results for the Year Ended December 31, 2019
GSK Egypt to Launch 2 Production Lines with EGP 100 million Investments
Glaxo Smith Kline Announces Consolidated Earning Results for the Nine Months Ended September 30, 2018
GlaxoSmithKline S.A.E Announces Consolidated and Standalone Earnings Results for the First Quarter Ended March 31, 2018
GlaxoSmithKline S.A.E Announces Consolidated and Standalone Earnings Results for the Six Months Ended June 30, 2018
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. BIOC Aktie
  4. Nachrichten GlaxoSmithKline S.A.E
  5. Andere Sprachen